| Year |
Citation |
Score |
| 2023 |
Harris B, Singh DK, Verma M, Fahl SP, Rhodes M, Sprinkle SR, Wang M, Zhang Y, Perrigoue J, Kessel R, Peri S, West J, Giricz O, Boultwood J, Pellagatti A, ... ... Steidl U, et al. Ribosomal protein control of hematopoietic stem cell transformation through direct, non-canonical regulation of metabolism. Biorxiv : the Preprint Server For Biology. PMID 37398007 DOI: 10.1101/2023.05.31.543132 |
0.392 |
|
| 2023 |
Konopleva M, DiNardo C, Bhagat T, Baran N, Lodi A, Saxena K, Cai T, Su X, Skwarska A, Guerra V, Kuruvilla V, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, ... ... Steidl U, et al. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses. Research Square. PMID 36865338 DOI: 10.21203/rs.3.rs-2518774/v1 |
0.326 |
|
| 2023 |
Ames K, Kaur I, Shi Y, Tong MM, Sinclair T, Hemmati S, Glushakow-Smith SG, Tein E, Gurska L, Steidl U, Dubin R, Shan J, Montagna C, Pradhan K, Verma A, et al. PI3-kinase deletion promotes myelodysplasia by dysregulating autophagy in hematopoietic stem cells. Science Advances. 9: eade8222. PMID 36812307 DOI: 10.1126/sciadv.ade8222 |
0.373 |
|
| 2022 |
Piszczatowski RT, Schwenger E, Sundaravel S, Stein CM, Liu Y, Stanley P, Verma A, Zheng D, Seidel RD, Almo SC, Townley RA, Bülow HE, Steidl U. A glycan-based approach to cell characterization and isolation: Hematopoiesis as a paradigm. The Journal of Experimental Medicine. 219. PMID 36066492 DOI: 10.1084/jem.20212552 |
0.309 |
|
| 2021 |
Rahmani NE, Ramachandra N, Sahu S, Gitego N, Lopez A, Pradhan K, Bhagat TD, Gordon-Mitchell S, Pena BR, Kazemi M, Rao K, Giricz O, Maqbool SB, Olea R, Zhao Y, ... ... Steidl U, et al. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer Journal. 11: 157. PMID 34548471 DOI: 10.1038/s41408-021-00541-0 |
0.376 |
|
| 2021 |
Taylor SJ, Sundaravel S, Steidl U. Exploiting a key transcriptional dependency: ZMYND8 and IRF8 in AML. Molecular Cell. 81: 3445-3446. PMID 34478652 DOI: 10.1016/j.molcel.2021.08.013 |
0.304 |
|
| 2021 |
Wheat JC, Steidl U. Gene expression at a single-molecule level: implications for myelodysplastic syndromes and acute myeloid leukemia. Blood. 138: 625-636. PMID 34436525 DOI: 10.1182/blood.2019004261 |
0.31 |
|
| 2021 |
Sundaravel S, Steidl U. Stem cell origins of JMML. The Journal of Experimental Medicine. 218. PMID 33427877 DOI: 10.1084/jem.20202152 |
0.356 |
|
| 2020 |
Amgalan D, Garner TP, Pekson R, Jia XF, Yanamandala M, Paulino V, Liang FG, Corbalan JJ, Lee J, Chen Y, Karagiannis GS, Sanchez LR, Liang H, Narayanagari SR, Mitchell K, ... ... Steidl U, et al. A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy. Nature Cancer. 1: 315-328. PMID 32776015 DOI: 10.1038/S43018-020-0039-1 |
0.34 |
|
| 2020 |
Wheat JC, Sella Y, Willcockson M, Skoultchi AI, Bergman A, Singer RH, Steidl U. Single-molecule imaging of transcription dynamics in somatic stem cells. Nature. PMID 32581360 DOI: 10.1038/S41586-020-2432-4 |
0.405 |
|
| 2020 |
Adrianzen-Herrera D, Choudhary G, Gordon-Mitchell S, Ramachandra N, Bhagat T, Zhang H, Aluri S, Shastri A, Steidl U, Will B, Yang WL, Mahler M, Eichenbaum G, Guha C, Verma A. The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation. Leukemia & Lymphoma. 1-13. PMID 32578476 DOI: 10.1080/10428194.2020.1775213 |
0.442 |
|
| 2020 |
Nguyen DT, Prieto C, Liu Z, Wheat J, Perez A, Gourkanti S, Chou T, Barin E, Chow A, Taggart J, Hoskova K, Dhodapkar M, Schurer A, Barlowe TS, Vu L, ... ... Steidl UG, et al. Transcriptional Control of HP1a By the RNA Binding Proteins Rbmx/L1 Maintain Chromatin State in Myeloid Leukemia Blood. 136: 15-15. DOI: 10.1182/BLOOD-2020-142229 |
0.35 |
|
| 2019 |
Bussel J, Kulasekararaj A, Cooper N, Verma A, Steidl U, Semple JW, Will B. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists. Seminars in Hematology. 56: 262-278. PMID 31836033 DOI: 10.1053/J.Seminhematol.2019.09.001 |
0.3 |
|
| 2019 |
Sridharan A, Schinke CD, Georgiev G, Da Silva Ferreira M, Thiruthuvanathan V, MacArthur I, Bhagat TD, Choudhary GS, Aluri S, Chen J, Pradhan K, Xia Y, Panjikaran M, Sims G, Bhagat CK, ... ... Steidl U, et al. Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. Blood Advances. 3: 3962-3967. PMID 31805192 DOI: 10.1182/Bloodadvances.2019000731 |
0.48 |
|
| 2019 |
Bhagat TD, Von Ahrens D, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel B, Kang C, Choudhary G, Gordon-Mitchell S, Aluri S, Bhattacharyya S, Sahu S, ... ... Steidl U, et al. Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. Elife. 8. PMID 31663852 DOI: 10.7554/Elife.50663 |
0.43 |
|
| 2019 |
Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly A, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Sridharan A, Gueorguieva I, Girvan A, da Silva Ferreira M, ... ... Steidl U, et al. Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31481511 DOI: 10.1158/1078-0432.Ccr-19-1338 |
0.317 |
|
| 2019 |
Mitchell K, Steidl U. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). Cold Spring Harbor Perspectives in Medicine. PMID 31451539 DOI: 10.1101/Cshperspect.A036251 |
0.451 |
|
| 2019 |
Willcockson MA, Taylor SJ, Ghosh S, Healton SE, Wheat JC, Wilson TJ, Steidl U, Skoultchi AI. Runx1 promotes murine erythroid progenitor proliferation and inhibits differentiation by preventing Pu.1 downregulation. Proceedings of the National Academy of Sciences of the United States of America. PMID 31431533 DOI: 10.1073/Pnas.1901122116 |
0.426 |
|
| 2019 |
Piszczatowski RT, Steidl U. Aurora Kinase A inhibition: A mega-hit for myelofibrosis therapy? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31196854 DOI: 10.1158/1078-0432.Ccr-19-1481 |
0.317 |
|
| 2019 |
Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, ... ... Steidl U, et al. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery. PMID 31101629 DOI: 10.1158/2159-8290.CD-1-18 |
0.307 |
|
| 2019 |
Smith MA, Choudhary GS, Pellagatti A, Choi K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V, Kim S, Steidl U, Walter M, Fraser IDC, Kulkarni A, et al. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nature Cell Biology. PMID 31011167 DOI: 10.1038/S41556-019-0314-5 |
0.403 |
|
| 2019 |
Mattes K, Geugien M, Korthuis PM, Brouwers-Vos AZ, Fehrmann RSN, Todorova TI, Steidl U, Vellenga E, Schepers H. Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells. Experimental Hematology. PMID 30986495 DOI: 10.1016/J.Exphem.2019.03.003 |
0.525 |
|
| 2019 |
Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, ... ... Steidl U, et al. Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis. Cancer Discovery. PMID 30944118 DOI: 10.1158/2159-8290.Cd-18-1138 |
0.417 |
|
| 2019 |
Chung EYL, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, Wei X, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, et al. PAK kinase inhibition has therapeutic activity in novel preclinical models of Adult T-cell Leukemia/Lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30862694 DOI: 10.1158/1078-0432.Ccr-18-3033 |
0.404 |
|
| 2019 |
Shenoy N, Bhagat TD, Cheville JC, Lohse C, Bhattacharyya S, Tischer A, Machha V, Gordon-Mitchell S, Choudhary GS, Wong LF, Gross L, Ressegue E, Leibovich BC, Boorjian SA, Steidl U, et al. Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcystosine loss in renal cell carcinoma. The Journal of Clinical Investigation. PMID 30702441 DOI: 10.1172/Jci98747 |
0.353 |
|
| 2019 |
Herrera DAA, Choudhary G, Bhagat T, Gordon-Mitchell S, Zhang H, Steidl U, Will B, Eichenbaum G, Guha C, Verma A. A novel thrombopoietin mimetic RWJ-800088 increases megakaryopoiesis without causing malignant proliferation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E18527 |
0.339 |
|
| 2019 |
Aluri S, Bachiashvili K, Budhathoki A, Bhagat TD, Choudhary GS, Gordon S, Ramachandra N, Pradhan K, Maqbool S, Shastri A, Huh JI, Hwang S, Seong-Jin K, Zhang H, Will B, ... ... Steidl UG, et al. Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS Blood. 134: 2990-2990. DOI: 10.1182/blood-2019-127561 |
0.302 |
|
| 2019 |
Choudhary GS, Smith MA, Pellagatti A, Bhagat TD, Gordon S, Pandey S, Shah N, Aluri S, Booher RN, Ramachandra M, Samson ME, Pradhan K, Bowman TV, Pillai MM, Guha C, ... ... Steidl UG, et al. SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML Blood. 134: 4224-4224. DOI: 10.1182/Blood-2019-124458 |
0.31 |
|
| 2019 |
Healy S, Ennishi D, Bashashati A, Saberi S, Hother C, Mottok A, Chan FC, Chong L, Kridel R, Boyle M, Meissner B, Aoki T, Takata K, Woolcock BW, Vigano E, ... ... Steidl U, et al. Abstract 3480:TMEM30Aloss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma Cancer Research. 79: 3480-3480. DOI: 10.1158/1538-7445.Am2019-3480 |
0.414 |
|
| 2019 |
Howe R, Bartholdy B, Schinke C, Rosenthal A, Lagano A, Parekh S, Steidl U. 2024 - Deficiency Of The Novel Tumor Suppressor C15Orf65 Causes Multiple Myeloma And Plasma Cell Malignancy Experimental Hematology. 76. DOI: 10.1016/J.Exphem.2019.06.296 |
0.417 |
|
| 2019 |
Steidl U. 1003 - Understanding And Targeting The Stem Cell Origins Of Myeloid Malignancies Experimental Hematology. 76. DOI: 10.1016/J.Exphem.2019.06.241 |
0.476 |
|
| 2018 |
Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, ... ... Steidl U, et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. The Journal of Clinical Investigation. PMID 30252677 DOI: 10.1172/Jci120156 |
0.532 |
|
| 2018 |
Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB, Verma A, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag. Science Translational Medicine. 10. PMID 30209246 DOI: 10.1126/Scitranslmed.Aas9563 |
0.431 |
|
| 2018 |
Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. IL1RAP potentiates multiple oncogenic signaling pathways in AML. The Journal of Experimental Medicine. PMID 29773641 DOI: 10.1084/Jem.20180147 |
0.442 |
|
| 2018 |
Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, ... ... Steidl U, et al. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Science Translational Medicine. 10. PMID 29643228 DOI: 10.1126/Scitranslmed.Aao3003 |
0.458 |
|
| 2018 |
Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY, et al. LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood. PMID 29453291 DOI: 10.1182/Blood-2017-09-807024 |
0.436 |
|
| 2018 |
Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari S, Thiruthuvanathan V, Montagna C, Will B, Verma A, Steidl U. MDS Progression to AML at the Stem Cell Level Experimental Hematology. 64: S48. DOI: 10.1016/J.Exphem.2018.06.063 |
0.437 |
|
| 2017 |
Kanna R, Choudhary G, Ramachandra N, Steidl U, Verma A, Shastri A. STAT3 inhibition as a therapeutic strategy for leukemia. Leukemia & Lymphoma. 1-7. PMID 29164994 DOI: 10.1080/10428194.2017.1397668 |
0.389 |
|
| 2017 |
Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, ... ... Steidl U, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. The Journal of Clinical Investigation. PMID 29083320 DOI: 10.1172/Jci92504 |
0.316 |
|
| 2017 |
Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E. Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia. Cancer Cell. 32: 490-505.e10. PMID 29017059 DOI: 10.1016/J.Ccell.2017.09.001 |
0.367 |
|
| 2017 |
Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, et al. Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways. Genome Research. PMID 28986391 DOI: 10.1101/Gr.222794.117 |
0.354 |
|
| 2017 |
Bhagat T, Chen S, Bartenstein M, Barlowe TS, von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, ... ... Steidl U, et al. Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome. Cancer Research. PMID 28684528 DOI: 10.1158/0008-5472.Can-17-0282 |
0.339 |
|
| 2017 |
Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, ... Steidl U, et al. A myeloid tumor suppressor role for NOL3. The Journal of Experimental Medicine. PMID 28232469 DOI: 10.1084/Jem.20162089 |
0.477 |
|
| 2017 |
Shastri A, Will B, Steidl U, Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood. PMID 28159737 DOI: 10.1182/Blood-2016-10-696062 |
0.471 |
|
| 2017 |
Carvajal LA, Ben-Neriah D, Senecal A, Bernard L, Narayanagari S, Kenworthy C, Thiruthuvanathan V, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa J, Mantzaris I, Aivado MA, Singer RH, ... ... Steidl UG, et al. Dual Inhibition of Mdmx and Mdm2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia Blood. 130: 795-795. DOI: 10.1182/Blood.V130.Suppl_1.795.795 |
0.324 |
|
| 2017 |
Bartenstein M, Yue L, Zhao W, Ho WT, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ, et al. Abstract 954: TGF-ß signaling inhibition counteracts myelofibrosis in MPN Cancer Research. 77: 954-954. DOI: 10.1158/1538-7445.Am2017-954 |
0.37 |
|
| 2017 |
Choudhary GS, Bhagat TD, Samson MES, Gordon S, Ahrens DV, Pradhan K, Shastri A, Pellagatti A, Boutlwood J, Booher RN, Steidl U, Verma A. Abstract 127: Efficacy of novel IRAK4 inhibitor CA4948 in AML and MDS Cancer Research. 77: 127-127. DOI: 10.1158/1538-7445.Am2017-127 |
0.457 |
|
| 2017 |
Shastri A, Teixeira M, Bhattacharya S, Ramachandra N, Lopez R, Ravipati G, Bhagat T, Choudhary G, Bartenstein M, Gordon-Mitchell S, Pradhan K, Pellagatti A, Boultwood J, Kim Y, Woessner R, ... ... Steidl U, et al. Therapeutic Targeting of MDS & AML Stem Cells with an Antisense Inhibitor of STAT3 Leukemia Research. 55: S8. DOI: 10.1016/S0145-2126(17)30128-5 |
0.349 |
|
| 2017 |
Antony-Debre I, Leite J, Paul A, Mitchell K, Kim HM, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari S, Carvajal LA, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, ... ... Steidl U, et al. Inhibition of the myeloid master regulator PU.1 as a therapeutic strategy in acute myeloid leukemia Experimental Hematology. 53: S133. DOI: 10.1016/J.Exphem.2017.06.337 |
0.381 |
|
| 2017 |
Carvajal L, Ben-Neriah D, Senecal A, Benard L, Narayanagari S, Kenworhty C, Thiruthuvanathan V, Guerlavais V, Annis A, Bartholdy B, Will B, Anampa J, Mantzaris I, Aivado M, Singer R, ... ... Steidl U, et al. Dual inhibition of HDMX and HDM2 in acute myeloid leukemia Experimental Hematology. 53: S46. DOI: 10.1016/J.Exphem.2017.06.058 |
0.34 |
|
| 2016 |
Carvajal LA, Steidl U. Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy. Cell Stem Cell. 19: 6-8. PMID 27392220 DOI: 10.1016/J.Stem.2016.06.005 |
0.43 |
|
| 2016 |
Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, ... ... Steidl U, et al. Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia. Cancer Research. PMID 27287719 DOI: 10.1158/0008-5472.Can-15-3062 |
0.483 |
|
| 2016 |
Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, Lakshminarasimhan R, Chin CP, Techner JM, Will B, Nerlov C, Steidl U, Manz MG, Schroeder T, Passegué E. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nature Cell Biology. PMID 27111842 DOI: 10.1038/Ncb3346 |
0.406 |
|
| 2016 |
Stanley RF, Steidl U. Ectopic DNMT3B expression delays leukemogenesis. Blood. 127: 1525-6. PMID 27013212 DOI: 10.1182/Blood-2016-01-692137 |
0.377 |
|
| 2016 |
Shastri A, Teixeira M, Bhattacharyya S, Ramachandra N, Lopez R, Ravipati G, Feld J, Dhar Y, Bhagat TD, Choudhary G, Giricz O, Bartenstein M, Sridharan A, Gordon-Mitchell S, Nawanko G, ... ... Steidl U, et al. Targeting MDS and AML Stem Cells with AZD-9150 Mediated Inhibition of STAT3 Blood. 128: 4314-4314. DOI: 10.1182/Blood.V128.22.4314.4314 |
0.506 |
|
| 2016 |
Darbinyan KA, Helbig D, Saleh Esa J, Budhathoki A, Goel S, Shastri A, Janakiram M, Kornblum N, Derman O, Gritsman K, Steidl U, Verma A, Braunschweig I, Mantzaris I. Hispanic Ethnicity Is Associated with Younger Age at Presentation and Worse Survival in AML Blood. 128: 3600-3600. DOI: 10.1182/Blood.V128.22.3600.3600 |
0.314 |
|
| 2016 |
Gritsman K, Hasserjian RP, Sinclair T, Weinstock DM, Will B, Steidl U, Ballen KK, Fathi AT, Verma A, Juric D, Amrein PC. Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109 Blood. 128: 2749-2749. DOI: 10.1182/Blood.V128.22.2749.2749 |
0.394 |
|
| 2016 |
Pietras E, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk L, Zhang S, Lakshminarasimhan R, Chin CP, Techner J, Will B, Nerlov C, Steidl U, Manz M, Schroeder T, Passegué E. The PRO-inflammatory cytokine interleukin-1 is a key regulator of hematopoietic Stem cell fate and function Experimental Hematology. 44: S49. DOI: 10.1016/J.Exphem.2016.06.066 |
0.388 |
|
| 2015 |
Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, ... ... Steidl U, et al. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America. 112: E6359-E6368. PMID 26578796 DOI: 10.1073/Pnas.1516394112 |
0.396 |
|
| 2015 |
Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, ... ... Steidl U, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nature Chemical Biology. PMID 26436839 DOI: 10.1038/Nchembio.1930 |
0.43 |
|
| 2015 |
Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Neriah DB, Roth M, van Oers J, Schaetzlein S, ... ... Steidl U, et al. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nature Medicine. PMID 26343801 DOI: 10.1038/Nm.3936 |
0.382 |
|
| 2015 |
Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood. PMID 26170031 DOI: 10.1182/Blood-2014-12-618801 |
0.494 |
|
| 2015 |
Antony-Debré I, Steidl U. Functionally relevant RNA helicase mutations in familial and sporadic myeloid malignancies. Cancer Cell. 27: 609-11. PMID 25965566 DOI: 10.1016/J.Ccell.2015.04.013 |
0.302 |
|
| 2015 |
Shih AH, Jiang Y, Meydan C, Shank K, Pandey S, Barreyro L, Antony-Debre I, Viale A, Socci N, Sun Y, Robertson A, Cavatore M, de Stanchina E, Hricik T, Rapaport F, ... ... Steidl U, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 27: 502-15. PMID 25873173 DOI: 10.1016/J.Ccell.2015.03.009 |
0.452 |
|
| 2015 |
Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, ... ... Steidl U, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 125: 3144-52. PMID 25810490 DOI: 10.1182/Blood-2015-01-621631 |
0.492 |
|
| 2015 |
Okoye-Okafor UC, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall K, Reif A, Schmidt S, Qi H, Zhao H, Joberty G, ... ... Steidl U, et al. New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia Blood. 126: 787-787. DOI: 10.1182/Blood.V126.23.787.787 |
0.477 |
|
| 2015 |
Pietras EM, Mirantes-Barbeito C, Fong S, Loffler D, Kovtonyuk LV, Lakshminarashimhan R, Chin CP, Techner J, Will B, Nerlov C, Steidl U, Manz M, Schroeder T, Passegue E. Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal Blood. 126: 778-778. DOI: 10.1182/Blood.V126.23.778.778 |
0.382 |
|
| 2015 |
Schepers H, Korthuis P, Geugien M, Jaques J, Todorova TI, Steidl U, Schuringa JJ, Vellenga E. CITED2 Cooperates with Low PU.1 and DNMT3A to Maintain Self-Renewal in Hematopoietic Stem Cells Blood. 126: 309-309. DOI: 10.1182/Blood.V126.23.309.309 |
0.506 |
|
| 2015 |
Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Chen J, Yu Y, Mayer J, Ferreira MdS, Barreyro L, Carvajal L, Roth M, Oers Jv, Schaetzlein S, McMahon C, ... ... Steidl U, et al. Minimal Reduction of PU.1 Is Sufficient to Induce a Preleukemic State and Promote Development of Acute Myeloid Leukemia Blood. 126: 305-305. DOI: 10.1182/Blood.V126.23.305.305 |
0.525 |
|
| 2015 |
Sigmans J, Noort W, Lindsley C, Pan L, Aalders L, Bariteau M, Ebert B, Aster J, Steidl U, Schuringa J, Yuan H, Bruijn Jd, Raymakers R, Lokhorst H, Mutis T, et al. Abstract PR12: Biological insights into tumor-bone marrow microenvironment interactions derived from a humanized murine model Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-Pr12 |
0.329 |
|
| 2015 |
Okoye-Okafor UC, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall K, Reif A, Schmidt S, Qi H, Zhao H, Joberty G, ... ... Steidl U, et al. Abstract C38: Novel allosteric IDH1 mutant Inhibitors for differentiation therapy of acute myeloid leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C38 |
0.478 |
|
| 2014 |
Antony-Debré I, Steidl U. CDK6, a new target in MLL-driven leukemia. Blood. 124: 5-6. PMID 24993876 DOI: 10.1182/Blood-2014-05-572917 |
0.403 |
|
| 2014 |
Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, Jordan CT, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. Molecular Cancer Therapeutics. 13: 1979-90. PMID 24934933 DOI: 10.1158/1535-7163.Mct-13-0963 |
0.387 |
|
| 2014 |
Will B, Steidl U. Combinatorial haplo-deficient tumor suppression in 7q-deficient myelodysplastic syndrome and acute myeloid leukemia. Cancer Cell. 25: 555-7. PMID 24823633 DOI: 10.1016/J.CCR.2014.05.014 |
0.36 |
|
| 2014 |
Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leukemia & Lymphoma. 55: 2901-6. PMID 24650011 DOI: 10.3109/10428194.2014.894186 |
0.41 |
|
| 2014 |
Will B, Steidl U. Stem cell fate regulation by dynein motor protein Lis1. Nature Genetics. 46: 217-8. PMID 24569235 DOI: 10.1038/Ng.2902 |
0.419 |
|
| 2014 |
Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat TD, Okoye-Okafor UC, Todorova TI, Greally JM, Levine RL, Melnick A, Verma A, Steidl U. HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. The Journal of Clinical Investigation. 124: 1158-67. PMID 24487588 DOI: 10.1172/Jci71264 |
0.437 |
|
| 2014 |
Elias HK, Schinke C, Bhattacharyya S, Will B, Verma A, Steidl U. Stem cell origin of myelodysplastic syndromes. Oncogene. 33: 5139-50. PMID 24336326 DOI: 10.1038/Onc.2013.520 |
0.494 |
|
| 2014 |
Basova P, Pospisil V, Savvulidi F, Burda P, Vargova K, Stanek L, Dluhosova M, Kuzmova E, Jonasova A, Steidl U, Laslo P, Stopka T. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene. 33: 4735-45. PMID 24121269 DOI: 10.1038/Onc.2013.414 |
0.365 |
|
| 2014 |
Shakaladevanapura Bachegowda L, Mantzaris I, Morrone KA, Keshkar N, Li W, Nwankwo G, Shahnaz S, Bhagat TD, Giricz O, Bhattacharrya S, Yu Y, Schinke CD, Pynadath A, Pellagatti A, Boultwood J, ... ... Steidl U, et al. Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 124: 4628-4628. DOI: 10.1182/Blood.V124.21.4628.4628 |
0.521 |
|
| 2014 |
Bowler TG, Bartenstein M, Morrone KA, Rohanizadegan M, Kessel RM, Hooda L, Datt I, Giricz O, Bhagat TD, Przychodzen BP, Parmar S, Gill JB, Yu Y, Maciejewski JP, Steidl U, et al. Exome Sequencing of Familial MDS Reveals Novel Mutations and High Rates of False Positive Mutations in MLL3 Due to Pseudogene Effects Blood. 124: 4591-4591. DOI: 10.1182/Blood.V124.21.4591.4591 |
0.328 |
|
| 2014 |
Bhagat TD, Bartenstein M, Yu Y, Marcondes AMQ, Will B, Giricz O, Sohal DP, Mantzaris I, Wickrema A, Mcmahon C, Cecilia Y, Greally J, Mukherjee S, Steidl U, Deeg HJ, et al. Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors Blood. 124: 4379-4379. DOI: 10.1182/Blood.V124.21.4379.4379 |
0.468 |
|
| 2014 |
Shastri A, Schinke C, Yanovsky AV, Bhagat TD, Giricz O, Barreyro L, Boultwood J, Pellagati A, Yu Y, Brown JR, Frank DA, Das B, Kambhampati S, Will B, Steidl U, et al. Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine Blood. 124: 3602-3602. DOI: 10.1182/Blood.V124.21.3602.3602 |
0.532 |
|
| 2014 |
Bhagat TD, Zhou L, Sokol L, Mantzaris I, Bhattacharyya S, Gordon SAK, Yu Y, Gundabolu K, Nischal S, Polineni R, Schinke C, Chrysofakis G, Wickrema A, Pellagatti A, Boultwood J, ... Steidl U, et al. Abstract 5224: MicroRNA mediated regulation of TGF-β signaling leads to stem cell alterations in myelodysplastic syndromes Cancer Research. 74: 5224-5224. DOI: 10.1158/1538-7445.Am2014-5224 |
0.401 |
|
| 2014 |
Okoye-Okafor UC, Barreyro L, Pujato M, Wang HR, Bartholdy B, Will B, Todorova TI, Kawahara M, Woolcock B, Fiser A, Gascoyne R, Steidl C, Steidl U. Abstract 2945: Characterization of a novel protein-coding gene named TIHL (Translocated in Hodgkin's Lymphoma) Cancer Research. 74: 2945-2945. DOI: 10.1158/1538-7445.Am2014-2945 |
0.489 |
|
| 2014 |
Will B, Todorova T, Verma A, Steidl U, Melnick A. Regulation of hematopoietic stem cell fate by special at-rich sequence binding protein 1 Experimental Hematology. 42. DOI: 10.1016/J.Exphem.2014.07.251 |
0.443 |
|
| 2013 |
Pathak S, Roth M, Verma A, Steidl U. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. Expert Opinion On Drug Metabolism & Toxicology. 9: 1667-75. PMID 24215532 DOI: 10.1517/17425255.2013.858119 |
0.334 |
|
| 2013 |
Bhattacharyya S, Yu Y, Suzuki M, Campbell N, Mazdo J, Vasanthakumar A, Bhagat TD, Nischal S, Christopeit M, Parekh S, Steidl U, Godley L, Maitra A, Greally JM, Verma A. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Research. 41: e157. PMID 23861445 DOI: 10.1093/Nar/Gkt601 |
0.302 |
|
| 2013 |
Bachegowda L, Gligich O, Mantzaris I, Schinke C, Wyville D, Carrillo T, Braunschweig I, Steidl U, Verma A. Signal transduction inhibitors in treatment of myelodysplastic syndromes. Journal of Hematology & Oncology. 6: 50. PMID 23841999 DOI: 10.1186/1756-8722-6-50 |
0.405 |
|
| 2013 |
Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, ... Steidl U, et al. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nature Immunology. 14: 437-45. PMID 23563689 DOI: 10.1038/Ni.2572 |
0.427 |
|
| 2013 |
Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, ... ... Steidl U, et al. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. Journal of Immunology (Baltimore, Md. : 1950). 190: 2966-75. PMID 23408834 DOI: 10.4049/Jimmunol.1202493 |
0.398 |
|
| 2013 |
Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, ... ... Steidl U, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 121: 2875-81. PMID 23390194 DOI: 10.1182/Blood-2011-12-397067 |
0.31 |
|
| 2013 |
Pandolfi A, Barreyro L, Steidl U. Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cells. Stem Cells Translational Medicine. 2: 143-50. PMID 23349328 DOI: 10.5966/Sctm.2012-0109 |
0.472 |
|
| 2013 |
Yu Y, Mo Y, Ebenezer D, Bhattacharyya S, Liu H, Sundaravel S, Giricz O, Wontakal S, Cartier J, Caces B, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, ... ... Steidl U, et al. High resolution methylome analysis reveals widespread functional hypomethylation during adult human erythropoiesis. The Journal of Biological Chemistry. 288: 8805-14. PMID 23306203 DOI: 10.1074/Jbc.M112.423756 |
0.379 |
|
| 2013 |
Giricz O, Gordon SAK, Barreyro L, Bhagat TD, Pellagatti A, Boultwood J, Yu Y, Steidl U, Verma A. Inhibition Of CXCR2 As a Therapeutic Strategy In AML and MDS Blood. 122: 484-484. DOI: 10.1182/Blood.V122.21.484.484 |
0.538 |
|
| 2013 |
Shih AH, Jiang Y, Shank K, Pandey S, Viale A, Sun Y, Socci N, Robertson A, de Stanchina E, Hricik T, Rapaport F, Woods B, Cimmino L, Barreyro L, Steidl U, et al. Epigenetic Profiling Of Leukemia Stem Cells In a Model Of TET2/FLT3-Mutant AML Blood. 122: 476-476. DOI: 10.1182/Blood.V122.21.476.476 |
0.539 |
|
| 2013 |
Pandolfi A, Bartholdy B, Will B, Stanley R, Todorova TI, McMahon C, Steidl U. H2.0-Like Homeobox (HLX) Causes Pre-Leukemic Myeloid Expansion and Initiates AML In Cooperation With FLT3-ITD Blood. 122: 4201-4201. DOI: 10.1182/Blood.V122.21.4201.4201 |
0.502 |
|
| 2013 |
Okoye-Okafor UC, Barreyro L, Wang HR, Bartholdy B, Will B, Todorova TI, Narayanagari S, Pujato M, Kawahara M, Woolcock BW, Gascoyne RD, Steidl C, Steidl U. Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in Hodgkin’s Lymphoma) in Hematopoiesis Blood. 122: 3680-3680. DOI: 10.1182/Blood.V122.21.3680.3680 |
0.48 |
|
| 2013 |
Bhattacharyya S, Yu Y, Suzuki M, Cambpell N, Mazdo J, Vasantkumar A, Bhagat TD, Nischal S, Steidl U, Godley L, Maitra A, Greally JM, Verma A. Abstract 4231: Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Cancer Research. 73: 4231-4231. DOI: 10.1158/1538-7445.Am2013-4231 |
0.319 |
|
| 2013 |
Barreyro L, Mitchell K, Will B, Bartholdy B, Zhou L, Todorova T, Stanley R, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling R, Cripe L, ... ... Steidl U, et al. Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C225 |
0.55 |
|
| 2012 |
Pandolfi A, Steidl U. HLX in AML: novel prognostic and therapeutic target. Oncotarget. 3: 1059-60. PMID 23888188 DOI: 10.18632/Oncotarget.705 |
0.547 |
|
| 2012 |
Kawahara M, Pandolfi A, Bartholdy B, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell. 22: 194-208. PMID 22897850 DOI: 10.1016/J.Ccr.2012.06.027 |
0.406 |
|
| 2012 |
Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, ... ... Steidl U, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 120: 2076-86. PMID 22753872 DOI: 10.1182/Blood-2011-12-399683 |
0.454 |
|
| 2012 |
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, ... ... Steidl U, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 120: 1290-8. PMID 22723552 DOI: 10.1182/Blood-2012-01-404699 |
0.511 |
|
| 2012 |
Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 120: 386-94. PMID 22627766 DOI: 10.1182/Blood-2011-12-399667 |
0.432 |
|
| 2012 |
Bruns I, Cadeddu RP, Brueckmann I, Fröbel J, Geyh S, Büst S, Fischer JC, Roels F, Wilk CM, Schildberg FA, Hünerlitürkoglu AN, Zilkens C, Jäger M, Steidl U, Zohren F, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood. 120: 2620-30. PMID 22517906 DOI: 10.1182/Blood-2011-04-347484 |
0.446 |
|
| 2012 |
Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia & Lymphoma. 53: 1999-2003. PMID 22448921 DOI: 10.3109/10428194.2012.679267 |
0.35 |
|
| 2012 |
Volpi SA, Verma-Gaur J, Hassan R, Ju Z, Roa S, Chatterjee S, Werling U, Hou H, Will B, Steidl U, Scharff M, Edelman W, Feeney AJ, Birshtein BK. Germline deletion of Igh 3' regulatory region elements hs 5, 6, 7 (hs5-7) affects B cell-specific regulation, rearrangement, and insulation of the Igh locus. Journal of Immunology (Baltimore, Md. : 1950). 188: 2556-66. PMID 22345664 DOI: 10.4049/Jimmunol.1102763 |
0.328 |
|
| 2012 |
Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayser S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, ... ... Steidl U, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. The Journal of Experimental Medicine. 209: 35-50. PMID 22231305 DOI: 10.1084/Jem.20110540 |
0.357 |
|
| 2012 |
Vlckova P, Stanek L, Burda P, Vargova K, Savvulidi F, Kapalova M, Steidl U, Stopka T. PU.1 and p53 Double Mutant Mice Develop Aggressive AML with Dysplastic Features Blood. 120: 769-769. DOI: 10.1182/Blood.V120.21.769.769 |
0.394 |
|
| 2012 |
Pandolfi A, Bartholdy B, Kawahara M, Barreyro L, Will B, Stanley R, Michael R, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U. H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia Blood. 120: 651-651. DOI: 10.1182/Blood.V120.21.651.651 |
0.529 |
|
| 2012 |
Schemionek M, Steidl U, Schwab A, Tenen DG, Mhairi C, Holyoake TL, Preisinger C, Mueller-Tidow C, Brümmendorf TH, Koschmieder S. Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation. Blood. 120: 2776-2776. DOI: 10.1182/Blood.V120.21.2776.2776 |
0.516 |
|
| 2012 |
Okoye-Okafor UC, Bartholdy B, Woolcock B, Kawahara M, Todorova TI, Gascoyne RD, Steidl C, Steidl U. Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells. Blood. 120: 2333-2333. DOI: 10.1182/Blood.V120.21.2333.2333 |
0.477 |
|
| 2012 |
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley R, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe LD, Fernandez HF, ... ... Steidl U, et al. Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML Blood. 120: 1875-1875. DOI: 10.1182/Blood.V120.21.1875.1875 |
0.546 |
|
| 2011 |
Wontakal SN, Guo X, Will B, Shi M, Raha D, Mahajan MC, Weissman S, Snyder M, Steidl U, Zheng D, Skoultchi AI. A large gene network in immature erythroid cells is controlled by the myeloid and B cell transcriptional regulator PU.1. Plos Genetics. 7: e1001392. PMID 21695229 DOI: 10.1371/Journal.Pgen.1001392 |
0.464 |
|
| 2011 |
Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, ... ... Steidl U, et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of Biological Chemistry. 286: 25211-23. PMID 21532034 DOI: 10.1074/Jbc.M111.235028 |
0.337 |
|
| 2011 |
Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, ... ... Steidl U, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 471: 377-81. PMID 21368758 DOI: 10.1038/Nature09754 |
0.399 |
|
| 2010 |
Will B, Steidl U. Multi-parameter fluorescence-activated cell sorting and analysis of stem and progenitor cells in myeloid malignancies. Best Practice & Research. Clinical Haematology. 23: 391-401. PMID 21112038 DOI: 10.1016/J.Beha.2010.06.006 |
0.464 |
|
| 2010 |
O'Brien KB, Alberich-Jordà M, Yadav N, Kocher O, Diruscio A, Ebralidze A, Levantini E, Sng NJ, Bhasin M, Caron T, Kim D, Steidl U, Huang G, Halmos B, Rodig SJ, et al. CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cells. Development (Cambridge, England). 137: 2147-56. PMID 20530543 DOI: 10.1242/Dev.037150 |
0.411 |
|
| 2010 |
Will B, Siddiqi T, Jordà MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobayashi S. Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood. 115: 2901-9. PMID 20160166 DOI: 10.1182/Blood-2009-03-209544 |
0.381 |
|
| 2010 |
Schemionek M, Elling C, Steidl U, Bäumer N, Hamilton A, Spieker T, Göthert JR, Stehling M, Wagers A, Huettner CS, Tenen DG, Tickenbrock L, Berdel WE, Serve H, Holyoake TL, et al. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood. 115: 3185-95. PMID 20053753 DOI: 10.1182/Blood-2009-04-215376 |
0.407 |
|
| 2009 |
Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 114: 3899-908. PMID 19710504 DOI: 10.1182/Blood-2009-04-219493 |
0.44 |
|
| 2009 |
Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AA, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M. Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome. International Journal of Hematology. 89: 173-87. PMID 19152102 DOI: 10.1007/S12185-008-0242-9 |
0.422 |
|
| 2009 |
Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal DP, Gundabolu K, Ng C, Mo Y, Wickrema A, Kong G, Friedman E, Sokol L, Burnette PK, ... Steidl U, et al. Dysregulation of TGF-Beta Stimulated Smad Signaling Is Seen in Myelodysplasia and Points to the Potential Therapeutic Efficacy of TGF-Beta Receptor I Kinase Inhibition in Low Grade Disease. Blood. 114: 737-737. DOI: 10.1182/Blood.V114.22.737.737 |
0.318 |
|
| 2009 |
Cadeddu R, Czibere AG, Büst S, Fischer JC, Steidl U, Kronenwett R, Kobbe G, Haas R, Bruns I. Neuropeptides Orexin A and B Are Funktionally Aktive in CD34+ Hematopoietic Stem and Progenitor Cells. Blood. 114: 4593-4593. DOI: 10.1182/Blood.V114.22.4593.4593 |
0.418 |
|
| 2008 |
Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, Singh R, Fenk R, Rosskopf M, Pechtel S, von Haeseler A, Wernet P, Tenen DG, Haas R, Kronenwett R. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica. 93: 347-55. PMID 18268278 DOI: 10.3324/Haematol.12081 |
0.425 |
|
| 2008 |
Bruns I, Czibere A, Cadeddu P, Roels F, Fischer JC, Büst S, Brünnert D, Steidl U, Brors B, Gattermann N, Kronenwett R, Haas R. Hematopoiesis in Chronic Phase CML emerges from Hematopoietic Stem Cells with a Transcriptional Phenotype Resembling Normal Myeloid Progenitor Cells. Blood. 112: 3365-3365. DOI: 10.1182/Blood.V112.11.3365.3365 |
0.495 |
|
| 2008 |
Bruns I, Cadeddu P, Büst S, Goerg B, Fischer JC, Selbach O, Steidl U, Kronenwett R, Haas R, Kobbe G, Czibere A. The Neuropeptides Orexin a and B Have An Impact on Functional Properties of Human CD34+ Stem and Progenitor Cells. Blood. 112: 1393-1393. DOI: 10.1182/Blood.V112.11.1393.1393 |
0.416 |
|
| 2008 |
Schemionek M, Agrawal S, Stehling M, Tenen DG, Hamilton A, Holyoake T, Steidl U, Berdel WE, Schwab A, Müller-Tidow C, Koschmieder S. Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells. Blood. 112: 1077-1077. DOI: 10.1182/Blood.V112.11.1077.1077 |
0.481 |
|
| 2007 |
Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. The Journal of Clinical Investigation. 117: 2611-20. PMID 17694175 DOI: 10.1172/JCI30525 |
0.31 |
|
| 2007 |
Steidl U, Steidl C, Ebralidze A, Chapuy B, Han H, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O’Brien KB, Verhaak RG, et al. A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia. Blood. 110: 3175-3175. DOI: 10.1182/BLOOD.V110.11.3175.3175 |
0.329 |
|
| 2007 |
Bruns I, Czibere AG, Fischer JC, Steidl U, Pechtel S, Koch A, Brünnert D, Büst S, Cadeddu R, Kronenwett R, Haas R. Molecular Signature of Distinct CD34+ Hematopoietic Stem and Progenitor Cell Subsets of Patients with CML in Chronic Phase. Blood. 110: 3170-3170. DOI: 10.1182/BLOOD.V110.11.3170.3170 |
0.428 |
|
| 2006 |
Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegué E, et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nature Genetics. 38: 1269-77. PMID 17041602 DOI: 10.1038/Ng1898 |
0.398 |
|
| 2006 |
Kronenwett R, Gräf T, Neumann F, Pechtel S, Steidl U, Diaz-Blanco E, Haas R. Absence of the JAK2 mutation V617F in CD34+ hematopoietic stem and progenitor cells from patients with BCR-ABL-positive CML in chronic phase and blast crisis. Leukemia Research. 30: 1323-4. PMID 16442619 DOI: 10.1016/j.leukres.2005.12.006 |
0.3 |
|
| 2006 |
Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion. 46: 180-5. PMID 16441592 DOI: 10.1111/J.1537-2995.2006.00699.X |
0.34 |
|
| 2006 |
Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL, Clayton LK, Wagner K, Scheller M, Iwasaki H, Liu C, Hackanson B, Akashi K, Leutz A, Rothstein TL, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nature Genetics. 38: 27-37. PMID 16311598 DOI: 10.1038/Ng1679 |
0.352 |
|
| 2005 |
Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG. Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia. International Journal of Hematology. 81: 368-77. PMID 16158816 |
0.308 |
|
| 2005 |
Steidl U, Schroeder T, Steidl C, Kobbe G, Graef T, Bork S, Pechtel S, Kliszewski S, Kuendgen A, Rohr UP, Fenk R, Schroeder M, Haase D, Haas R, Kronenwett R. Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera. Annals of the New York Academy of Sciences. 1044: 94-108. PMID 15958702 DOI: 10.1196/annals.1349.013 |
0.341 |
|
| 2005 |
Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood. 106: 1519-24. PMID 15914558 DOI: 10.1182/blood-2005-02-0717 |
0.363 |
|
| 2005 |
Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, Blanco ED, Roes N, Gräf T, Brors B, Eils R, Maercker C, Kobbe G, Gattermann N, Haas R. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene. 24: 5313-24. PMID 15806158 DOI: 10.1038/sj.onc.1208596 |
0.345 |
|
| 2005 |
Bruns I, Steidl U, Kobbe G, Fenk R, Kliszewski S, Pechtel S, Haas R, Kronenwett R. Distinct Gene Expression Pattern of CD34+ Stem and Progenitor Cells Mobilized by Pegfilgrastim after Cytotoxic Therapy in Multiple Myeloma in Comparison to G-CSF. Blood. 106: 5191-5191. DOI: 10.1182/BLOOD.V106.11.5191.5191 |
0.31 |
|
| 2005 |
Steidl U, Rosenbauer F, Verhaak RG, Gu X, Otu HH, Kolia S, Owens BM, Klippel S, Wagner K, Aivado M, Passegue E, Libermann TA, Delwel R, Tenen DG. Essential Role of Jun Family Transcription Factors in PU.1-Induced Leukemic Stem Cell Transformation. Blood. 106: 463-463. DOI: 10.1182/BLOOD.V106.11.463.463 |
0.396 |
|
| 2005 |
Kronenwett R, Diaz-Blanco E, Graef T, Steidl U, Kliszewski S, Bruns I, Neumann F, Bork S, Butterweck U, Roes N, Brors B, Eils R, Kobbe G, Gattermann N, Haas R. Molecular Phenotype of Malignant CD34+ Hematopoietic Stem and Progenitor Cells in Chronic Myelogenous Leukemia. Blood. 106: 2863-2863. DOI: 10.1182/BLOOD.V106.11.2863.2863 |
0.373 |
|
| 2005 |
Owens BM, Yu L, Steidl U, Kutok JL, Clayton LK, Wagner K, Iwasaki H, Liu C, Hackanson B, Akashi K, Plass C, Tenen DG, Rosenbauer F. Identification of ID4 as a Cooperating Second Hit for T Cell Lymphoma Development in PU.1 UREΔ/Δ Mice. Blood. 106: 2613-2613. DOI: 10.1182/Blood.V106.11.2613.2613 |
0.357 |
|
| 2004 |
Rosenbauer F, Steidl U, Owens B, Clayton L, Wagner K, Kutok JL, Beau MML, Tenen DG. Deletion of a Key PU.1 Gene Regulatory Element Induces T-Cell Lymphoma. Blood. 104: 344-344. DOI: 10.1182/Blood.V104.11.344.344 |
0.45 |
|
| 2004 |
Neumann F, Teutsch N, Kliszewski S, Bork S, Brors B, Schimkus N, Roes N, Steidl U, Germing U, Hildebrandt B, Royer-Pokora B, Eils R, Gattermann N, Haas R, Kronenwett R. Gene Expression Profiling of Philadelphia Chromosome(Ph) Negative CD34+ Hematopoietic Stem and Progenitor Cells of Patients with Ph Positive CML in Complete Molecular Remission during Therapy with Imatinib. Blood. 104: 2955-2955. DOI: 10.1182/BLOOD.V104.11.2955.2955 |
0.337 |
|
| 2004 |
Steidl U, Rosenbauer F, Gu X, Owens B, Klippel S, Wagner K, Aivado M, Libermann TA, Tenen DG. Knockdown of the Transcription Factor PU.1 Causes Characteristic Transcriptional Changes in Hematopoietic Stem Cells Prior to Leukemic Transformation. Blood. 104: 1112-1112. DOI: 10.1182/BLOOD.V104.11.1112.1112 |
0.371 |
|
| 2003 |
Steidl U, Kronenwett R, Martin S, Haas R. Molecular biology of hematopoietic stem cells. Vitamins and Hormones. 66: 1-28. PMID 12852251 |
0.388 |
|
| 2003 |
Steidl U, Kronenwett R, Haas R. Differential gene expression underlying the functional distinctions of primary human CD34+ hematopoietic stem and progenitor cells from peripheral blood and bone marrow. Annals of the New York Academy of Sciences. 996: 89-100. PMID 12799287 |
0.344 |
|
| 2002 |
Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, Maercker C, Neubert P, Aivado M, Koch J, Modlich O, Bojar H, Gattermann N, Haas R. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood. 99: 2037-44. PMID 11877277 |
0.335 |
|
| 1999 |
Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability Nucleic Acids Research. 27: 4328-4334. PMID 10536139 DOI: 10.1093/Nar/27.22.4328 |
0.321 |
|
| 1998 |
Kronenwett R, Steidl U, Kirsch M, Sczakiel G, Haas R. Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood. 91: 852-862. DOI: 10.1182/Blood.V91.3.852 |
0.431 |
|
| Show low-probability matches. |